Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy
Titel:
Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy
Auteur:
Tom, Martin C. Reddy, Chandana A. Smile, Timothy D. Zhang, Ryan X. Ciezki, Jay P. Stephans, Kevin L. Mian, Omar Y. Klein, Eric A. Campbell, Steven Ulchaker, James Angermeier, Kenneth Tendulkar, Rahul D.